Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3313249 | 0.73 | TDO2 (0.35) | TDO2 | |
| SCHEMBL12079012 | 0.73 | — | — | |
| SCHEMBL7339315 | 0.71 | — | — | |
| SCHEMBL460791 | 0.70 | ITGB3 (0.30) | — | |
| SCHEMBL923707 | 0.65 | — | — | |
| Water SCHEMBL10621554 | 0.65 | GAA (0.31) | — | |
| SCHEMBL10157505 | 0.65 | — | — | |
| SCHEMBL10436109 | 0.64 | — | — | |
| SCHEMBL19032024 | 0.64 | — | — | |
| Hydrochloric Acid SCHEMBL10660266 | 0.64 | GAA (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114957119-A | Tetrahydroquinaxospiro 1, 3-indandione derivative and preparation method and application thereof | 武汉大学中南医院 | 2022-08-30 | — | — | CN | claimed |
| EP-4017854-B1 | PYRAZINO[1,2-B]QUINAZOLINE-3,6-DIONES DERIVATIVES, THEIR PRODUCTION AND USES THEREOF | CIIMAR CENTRO INTERDISCIPLINAR DE INVESTIG MARINHA E AMBIENTAL (PT) | 2025-08-13 | — | — | EP | disclosed |
| CN-114040911-B | As NAV1.8 2, 3-Dihydro-quinazoline Compounds as inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-10-22 | — | — | CN | disclosed |
| EP-4419094-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | Edison Oncology (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | EDISON ONCOLOGY (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4297746-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED COMPOUNDS AND THERAPIES FOR THE TREATMENT OF DISEASES | Edison Oncology (US) | 2024-01-03 | — | — | EP | disclosed |
| WO-2023069727-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | EDISON ONCOLOGY (US) | 2023-04-27 | — | — | WO | disclosed |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
| US-20220274987-A1 | PYRAZINO [1,2-B]QUINAZOLINE-3,6-DIONES DERIVATIVES, THEIR PRODUCTION AND USES THEREOF | UNIVERSIDADE NOVA DE LISBOA (PT) | 2022-09-01 | — | — | US | disclosed |
| CN-114957119-A | Tetrahydroquinaxospiro 1, 3-indandione derivative and preparation method and application thereof | 武汉大学中南医院 | 2022-08-30 | — | — | CN | disclosed |
| US-5620976-A | PREVENTION AND TREATMENT OF DISEASES DUE TO INSUFFICIENCY OF THE CENTRAL CHOLINE FUNCTIONS | EISAI CO., LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| EP-0742216-A2 | Cyclic amide derivatives | Eisai Co., Ltd. (JP) | 1996-11-13 | — | — | EP | disclosed |
| US-5521182-A | ACETYLCHOLINESTERASE INHIBITORS | EISAI CO., LTD. (JP) | 1996-05-28 | — | — | US | disclosed |
| US-5504088-A | ACETYLCHOLINE ESTERASE INHIBITORS; ALZHEIMER'S DISEASE AND OTHER DISEASES CAUSED BY A LOW CONCENTRATION OF CHOLINE | EISAI CO., LTD. (JP) | 1996-04-02 | — | — | US | disclosed |
| EP-0677516-A1 | Cyclic amide derivatives | Eisai Co., Ltd. (JP) | 1995-10-18 | — | — | EP | disclosed |
| US-5292735-A | Cyclic amide derivatives | EISAI CO., LTD. (JP) | 1994-03-08 | — | — | US | disclosed |
| EP-0468187-A2 | Cyclic amide derivatives | Eisai Co., Ltd. (JP) | 1992-01-29 | — | — | EP | disclosed |
| US-4066665-A | CHEMICAL INTERMEDIATES FOR QUINAZOLINONES | SANDOZ, INC. (US) | 1978-01-03 | — | — | US | disclosed |
| US-3996227-A | 7-Methyl-1-isopropyl-4-phenyl-5,6,7,8-tetrahydro-2(1H)-quinazolinone | SANDOZ, INC. (US) | 1976-12-07 | — | — | US | disclosed |
| US-3870720-A | POTASSIUM DERIVATIVES OF 2-PHENYL-6-SULPHAMYL-7-CHLORO-1,2,3,4-TETRAHYDRO-4-QUINAZOLINONE | CARISSIMI MASSIMO | 1975-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274987-A1 | PYRAZINO [1,2-B]QUINAZOLINE-3,6-DIONES DERIVATIVES, THEIR PRODUCTION AND USES THEREOF | NQO2, G6PD, QDPR | TDO2 546/4885 |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DCK, CDC7, DNMT1 | TDO2 1843/4885 |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | TOP2A, TOP2B, TOP1 | TDO2 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.